Professor Guiying Nie, NHMRC Senior Research Fellow

Biography

A respected reproductive biologist and authority on uterine receptivity and placental development, Professor Guiying Nie obtained her PhD from the University of Essex, UK. She then travelled to the United States where she completed postdoctoral training at the Brookhaven National Laboratory in New York. In 1995, she joined Prince Henry’s Institute, now Hudson Institute of Medical Research, and embarked on research in reproductive biology. Now a Fellow of the Society of Reproductive Biology, she remains fascinated by this exciting area of research.

With a focus on the uterus and intrauterine environment for embryo implantation, placental development, and long-term health consequences, Prof Nie works closely with specialist clinicians to address key women’s health issues. Her current research interests include uterine infertility and receptivity for embryo implantation, non-hormonal contraception, endometrial cancer, placental development and diseases of pregnancy, particularly pre-eclampsia.

Prof Nie’s research has resulted in over 100 peer-reviewed publications, the majority as first or senior author in top discipline-specific or high impact general journals. A sought after speaker, she has presented her work at numerous national and international conferences and is regularly asked to review major national and international grants. She has also served on a number of editorial boards, including a current position on the Editorial Board of Reproductive Sciences.

As well as the National Health and Medical Research Council of Australia, Prof Nie receives funding support from Monash IVF, the CASS Foundation and international funding bodies such as CONRAD/CICCR (USA), Ferring, and the Bill and Melinda Gates Foundation.

Selected publications

  • Wang Y, Li Y, Hyett J, da Silva Costa F, Nie G (2016) HtrA3 isoform-specific ELISAs for early detection of preeclampsia. J Biomol Screen. DOI: pii: 1087057116682425.

  • Chen Q, Wang Y, Zhao M, Hyett J, Costa FS, Nie G (2016) Serum levels of GDF15 are reduced in preeclampsia and the reduction is more profound in late-onset than early-onset cases. Cytokine 83:226-230.

  • Heng S, Vollenhoven B, Rombauts LJ and Nie G (2015) A high-throughput assay for the detection of a-dystroglycan N-terminus in human uterine fluid to determine uterine receptivity. J Biomol Screen 21(4):408-413.

  • Heng S, Paule SG, Li Y, Rombauts LJ, Vollenhoven B, Salamonsen LA and Nie G (2015) Post-translational removal of alpha-dystroglycan N-terminus by PC5/6 cleavage is important for uterine preparation for embryo implantation in women FASEB 29:4011-4022.

  • Teoh SS, Zhao M, Wang Y, Chen Q Nie G (2015) Serum HtrA1 is differentially regulated between early-onset and late-onset preeclampsia. Placenta 36:990-995.

  • Singh H, Zhao M, Chen Qi, Wang Y, Li Y, Kaitu’u-Lino TJ, Tong S,  Nie G (2015) Human HtrA4 expression is restricted to the placenta, is significantly up-regulated in early-onset preeclampsia, and high levels of HtrA4 cause endothelial dysfunction. JCEM 100:E936-E945.

  • Paule S, Nebl T, Webb AL, Vollenhoven B, Rombauts LJF, Nie G (2015) Proprotein convertase 5/6 cleaves platelet derived growth factor A in the human endometrium in preparation for embryo implantation. Mol Hum Reprod 21:262-270.

  • Heng S, DynonK, Li Y, Edgell T, Rombauts LJ, Vollenhoven B, Nie G (2015) Development of a high throughput assay for human proprotein convertase 5/6 for detecting uterine receptivity. Anal Biochem 475:14-21.

  • Singh H, Nero TL, Wang Y, Parker MW, Nie G (2014) Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities. PLoS One 7(9):e45956.

  • Ho H, Li Y, Nie G (2014) Inhibition of embryo implantation in mice through vaginal administration of a proprotein convertase 6 inhibitor. Reproductive Biology 14:155-159.

  • Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN, Nie G (2013) HtrA3 is downregulated in cancer cell lines and significantly reduced in primary serous and granulosa cell ovarian tumors. J Cancer 4:152-164.